Clinical Trial Update: Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2 [Phase 2]

View source ↗

Summary

The sponsor reports completion of a Phase 2 trial evaluating valacyclovir plus celecoxib for Post-Acute Sequelae of SARS-CoV-2 infection (Long COVID).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Covid
• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• Celecoxib (Celecoxib)
• Valacyclovir (Valacyclovir)

Snippet

Sponsor: Bateman Horne Center | Conditions: Long COVID, PASC Post Acute Sequelae of COVID 19 | Phase 2 | Status: COMPLETED